Abstract. Accurate detection of neuroendocrine (NE) tumors is critically important for better prognosis and treatment outcomes in patients. To demonstrate the efficacy of using an adenoviral vector for the detection of NE tumors, we have constructed a pair of adenoviral vectors which, in combination, can conditionally replicate and release Gaussia luciferase into the circulation after infecting the NE tumors. The expression of these two vectors is regulated upstream by an INSM1-promoter (insulinoma-associated-1) that is specifically active in NE tumors and developing NE tissues, but silenced in normal adult tissues. In order to retain the tumorspecificity of the INSM1 promoter, we have modified the promoter using the core insulator sequence from the chicken β-globin HS4 insulator and the neuronal restrictive silencing element (NRSE). This modified INSM1-promoter can retain NE tumor specificity in an adenoviral construct while driving a mutated adenovirus E1A gene (∆24E1A), the Metridia, or Gaussia luciferase gene. The in vitro cell line and mouse xenograft human tumor studies revealed the NE specificity of the INSM1-promoter in NE lung cancer, neuroblastoma, medulloblastoma, retinoblastoma, and insulinoma. When we combined the INSM1-promoter driven Gaussia luciferase with ∆24E1A, the co-infected NE tumor secreted higher levels of Gaussia luciferase as compared to the INSM1p-Gaussia virus alone. In a mouse subcutaneous xenograft tumor model, the combination viruses secreted detectable level of Gaussia luciferase after infecting an INSM1-positive NE lung tumor for ≥12 days. Therefore, the INSM1-promoter specific conditional replicating adenovirus represents a sensitive diagnostic tool to aid clinicians in the detection of NE tumors.
Introduction
Neuroendocrine (NE) carcinomas are rare neoplasms that can develop into highly malignant and life-threatening tumors (1, 2) . While they share a number of genetic and phenotypic traits, NE carcinomas comprise a very heterogeneous population of tumor types that can arise in various organs throughout the body. The most common of these cancers include neuroblastomas, retinoblastomas, medulloblastomas, pituitary carcinomas, small cell lung carcinomas, and carcinoid tumors, encompassing a broad spectrum of tumors that have so far required multiple detection and treatment methods (3) (4) (5) (6) (7) . Despite their differences, many of these tumors express common tumor-specific markers that can identify them as NE cancers (8, 9) . Consequently, early detection of these tumor markers can lead to better treatment response and outcomes. The INSM1 gene encodes a NE tumor-specific marker that was discovered using an insulinoma subtractive hybridization screen (10, 11) . The INSM1-promoter regulates the expression of INSM1, a transcription factor with a zinc-finger DNA binding domain that is highly specific for NE tumors (12) . Through an Insm1 knockout mouse model, Insm1 transcription factor was found to be important in the formation of endocrine pancreas and sympatho-adrenal lineage during development (13, 14) . Most interestingly, INSM1 expression was discovered to be restricted to the embryonic peripheral and central nervous system, specifically in the cells of neuroendocrine origin (15) . The expression pattern was detected in the embryonic tissues of pituitary, pancreas, stomach, duodenum, thymus, adrenal glands, brain, and spinal cord, which were all found to be Insm1-positive at E15.5 in mice (16, 17) . However, INSM1 is silenced in normal adult tissues, but reactivated in most of the human NE tumors, including neuroblastoma, medulloblastoma, pheochromocytoma, small cell lung carcinoma, insulinomas, pituitary tumors, carcinoid tumors, medullary thyroid carcinoma, and retinoblastoma (18) . Therefore, INSM1 is a NE-specific tumor marker.
In order to assist with the detection of NE tumors despite their heterogeneous population, we have taken advantage of the INSM1-promoter's specificity in NE tumors to drive the expression of a downstream Gaussia luciferase gene. Secreted luciferases like Metridia or Gaussia luciferase have been shown to be highly luminescent, exhibiting 2-4-fold higher signal than Renilla or firefly luciferases (19, 20) . We have constructed INSM1p-Met and INSM1p-Gau reporter vectors to measure the INSM1 promoter activity in NE tumors. In vitro cell lines and xenograft human tumor cultured cells revealed positive luciferase secreted from NE tumors. In addition, combining the INSM1p-∆24E1A and INSM1p-Gau luciferase vectors increased the sensitivity of secreted Gaussia in vivo. The ∆24E1A gene, a mutant form of the adenovirus E1A gene with a 24-bp deletion, is inactive in retinoblastoma (Rb) protein expressing cells and active in Rb-negative cancer cells (21) . The cancer specificity from the modified INSM1 promoter and the ∆24E1A gene create a dual layer of safety against non-specific expression.
Materials and methods

Construction of adenoviral vectors.
The Ad-INSM1p-Met construct was cloned using an original pGL3-INSM1p vector that contained the modified INSM1-promoter with HS4 insulator upstream and 2X NRSE downstream (22) . The Metridia luciferase gene was excised from the pMetReporter vector (Clontech, Mountain View, CA, USA) and ligated downstream of the modified INSM1-promoter in pGL3. The pGL3 vector was cut to release the INSM1p-Met fragment, which was then ligated into the pShuttle plasmid (Agilent Technologies, Santa Clara, CA, USA) for adenoviral vector. The Ad-INSM1p-Gau and Ad-INSM1p-∆24E1A constructs were cloned using the modified INSM1-promoter on the pGL3-INSM1p vector, created by shortening the full insulator sequence into two copies of the core HS4 insulator. The Gaussia luciferase gene was obtained from the pMCSGaussia-Dura Luc vector (Thermo Fisher Scientific, Waltham, MA, USA) and ligated downstream of the INSM1-promoter to create pGL3-INSM1p-Gau. To clone the ∆24E1A gene, site directed mutagenesis was performed on an existing E1A gene in the pJet plasmid (Thermo Fisher Scientific) to delete 24 bp from the original sequence. This ∆24E1A gene was then cloned into the pGL3 vector to form pGL3-INSM1p-∆24E1A. Both the INSM1p-Gau and the INSM1p-∆24E1A fragments were excised from their vectors and placed into the pShuttle plasmid. The Ad-SV40-Luc2 construct was generated by excising the SV40 promoter from the pSEAP2-Control vector (Clontech) and ligated upstream of the Luc2 reporter gene in the pGL4.10 vector (Promega, Madison, WI, USA). The SV40-Luc2 fragment was cloned into the pShuttle vector. The pShuttle plasmid was linearized and electroporated into BJ5183-AD-1 cells (Agilent Technologies) to undergo recombination. After selection for the recombinants, linear adenoviral DNA was transfected into AD293 cells (Agilent Technologies) using FuGENE 6 reagent (Promega). The virus was amplified onto forty 150-mm tissue culture dishes and purified by CsCl gradient. This purified virus was then titered using the Adeno-X-Rapid Titer kit (Clontech, Mountain View) and stored at -80˚C. All sequences in the cloning process were verified through DNA sequencing.
In vivo luciferase imaging. Nu/Nu mice (National Cancer Institute, Bethesda, MD, USA), aged 8-10 weeks, received intravenous tail vein injection of either the modified first generation Ad-INSM1p-Luc2, the second generation Ad-INSM1p-Luc2, or unmodified Ad-INSM1p-Luc2. The viruses were prepared in phosphate-buffered saline at a concentration of 10 10 ifu/ml and 100 µl of the viral solution was delivered slowly into the tail vein via a 27-gauge needle. To perform the imaging analysis for luciferase activity, D-luciferin substrate (Biosynth, Itasca, IL, USA) was prepared at a concentration of 15 mg/ml and injected intraperitoneally into mice at a dose of 150 mg/kg. Once injection was completed, the mice were anesthetized in an isofluorane chamber (2-4% by inhalation) before being transferred to a kodak In-Vivo Multispectral FX imager (Carestream Health, Rochester, NY, USA). Using the imager's software, luminescence was acquired with a 10-min exposure and an X-ray image of the mice in the same position was acquired with a 2-min exposure. Imaging was performed 48 h after virus injection and periodically for ≤28 days. To generate the complete image, the luminescence acquisition was converted into a rainbow intensity scale and superimposed onto the X-ray acquisition using ImageJ software (National Institutes of Health, Bethesda MD, USA). For the NE tumor imaging, H1155 NE lung tumor cells (1x10 7 ) were pre-infected with the second generation modified Ad-INSM1p-Luc2 virus (50 MOI) for 24 h and injected subcutaneously into the right hind flank of nude mice (n=3). After one week, the tumor growth was evidenced and imaged to show the modified INSM1 promoter specificity.
In vitro Metridia and Gaussia luciferase secretion assay.
Cells were seeded in a 96-well plate at a density of 10,000 cells per well. After incubation at 37˚C and 5% CO 2 for 1 h, cells were infected with either no virus (negative control), Ad-INSM1p-Met (0-50 MOI), Ad-INSM1p-Gau (0-50 MOI), or Ad-SV40-Luc2 (5 MOI). Infected cells were then incubated at 37˚C, 5% CO 2 for 24 h. After incubation, each well was washed gently with 1X PBS and replaced with fresh media for another 24 h. Fifty microliters of media per well were transferred to a 96-well white microplate. Luminescence was detected using the Pierce Gaussia Luciferase Glow Assay kit (Thermo Fisher Scientific), and read on a TopCount NXT Microplate Scintillation and Luminescence Counter. The adenoviral infection efficiency was determined by normalization (ratio) with intracellular luciferase (Ad-SV40-Luc2) using the Dual-Glo luciferase assay system (Promega) and read on a TopCount NXT Microplate Scintillation and Luminescence counter. To test the effects of Ad-INSM1p-Gau in combination with the Ad-INSM1p-∆24E1A conditionally replicating adenovirus, cells were infected with a combination of 10 MOI Ad-INSM1p-Gau and Ad-INSM1p-∆24E1A for a total of 20 MOI (2x10 5 ifu). Media was collected 2, 4, and 6 days (20 µl each day) after infection to determine secreted luciferase activity. Luminescence was detected using the Pierce Gaussia Luciferase Glow Assay kit (Thermo Fisher Scientific), then read on a TopCount NXT Microplate Scintillation and Luminescence Counter. The Student's t-test with a threshold of p<0.05 was used to determine statistical significance. This process was repeated with the Ad-INSM1p-Gau infected cells to determine the Ad-INSM1p-Gau/Ad-SV40-Luc2 ratio.
Xenograft human tumor culture assay. Xenograft tumors were prepared by injecting human tumor cells (1x10 7 ), such as HeLa, U87, D283, UMC-11, SK-NBe(2), H1155, and H69 subcutaneously into the right hind flank of nude mice. Tumor tissues were harvested and frozen (-80˚C) in RPMI-1640 culture medium with 10% DMSO. The cultured tumor cells were prepared by rapidly thawing in a 37˚C water bath and subsequent mincing into small sections ~1 mm 3 in size. The minced tissues were then centrifuged at 250 x g for 1 min and incubated in 2.5% trypsin for a total of 30 min at 37˚C and 2 ml growth media was added to neutralize the trypsin. The trypsinized tissues were then filtered through a 70-µm sieve and centrifuged again at 250 x g for 5 min. The 96-well clearbottom plates were coated with 75 µl per well of a 1:6 dilution of Matrigel in RPMI growth media and then incubated for 30 min at 37˚C. The tumor cells (10,000 cells) were re-suspended in RPMI media and added to each Matrigel coated well. Cells from each tumor were infected with Metridia-luciferase and Ad-SV40-Luc2 at 37˚C for 24 h. The ratio of Metridia/Luc2 luciferase was calculated and averaged using RFU from 50 µl media per well.
Detection of serum Gaussia luciferase in vivo.
Eight-week-old Nu/Nu mice (National Cancer Institute) were injected with H1155 NE lung tumor cells (1x10 7 ) subcutaneously into the right hind flank. Tumors were allowed to establish until tumor size grew to ≥0.1 cm 3 in volume. The mice were injected intra-tumorally with 1x10 9 ifu of Ad-INSM1p-Luc2 virus, or a combination of 5x10 8 ifu of Ad-INSM1p-Gau and Ad-INSM1p-∆24E1A (for a total of 1x10 9 ifu). To detect the Gaussia expression in the bloodstream, 100 µl of blood was drawn at 3, 6, 9, and 12 days after virus injection. All animal experiments were performed in accordance with the approved protocol from the Institutional Animal Care and Use Committee, Louisiana State University Health Sciences Center New Orleans. The collected blood was allowed to clot for 30 min at room temperature and centrifuged at 2,000 g for 10 min. Serum was collected from the supernatant and diluted with PBS at a 1:10 ratio. To detect Gaussia luciferase in the serum, 50 µl of the diluted serum from each sample was added to a flat bottom 96-well plate for the Gaussia luciferase assay.
Statistical analysis.
Values were corrected and expressed relative to a control group. All experiments were repeated three times. Results are presented as mean ± SEM. Statistical analysis was performed using wither the Student's t-test when only two groups were in the experiment or by an one-way ANOVA comparison of multiple groups using the Tukey-kramer test with differences at p-value of <0.05 being considered significant.
Results
Cloning the INSM1-promoter driven adenoviral constructs.
To generate an adenoviral vector that is useful for the diagnosis of INSM1-positive NE tumors, we constructed the first generation modified INSM1-promoter by inserting a full HS4 insulator sequence upstream of the INSM1-promoter (~1.7 kb) along with two NRSE enhancer sequences in tandem repeats downstream and Luc2 gene (Fig. 1A) (22) . The modified INSM1-promoter drives a downstream Metridia luciferase gene, resulting in the construct Ad-HS4ins-INSM1p-2xNRSE-Metridia (Ad-INSM1p-Met) (Fig. 1B) . A second generation of the modified INSM1-promoter was constructed to drive the expression of Gaussia luciferase and ∆24E1A. This promoter was created using two copies of the HS4 core insulator in place of the full insulator sequence. The final constructs Ad-2xHS4Core-I NSM1p-2x N RSE-Gaussia (Ad-I NSM1p-Gau) a nd Ad-2xHS4Core-INSM1p-2xNRSE-∆24E1A (Ad-INSM1p-∆24E1A), have a modified INSM1-promoter that is ~700 bp shorter than that of the promoter in Ad-INSM1p-Met (Fig. 1C  and D) . Ad-SV40-Luc2 vector was constructed as a control vector (Fig. 1E) .
We tested whether an adenoviral vector driven by the modified INSM1-promoter would result in non-specific expression in vivo. Tail vein injection was performed using three viral vectors, the unmodified Ad-INSM1p-Luc2 (Fig. 1F) , the first generation of the modified Ad-INSM1p-Luc2 (Fig. 1G) , and the second generation modified Ad-INSMp-Luc2 (Fig. 1H ) injected into non-tumor bearing Nu/Nu mice separately. Therefore, we examined the INSM1 promoter specificity with or without HS4 insulator and NRSE enhancer sequence. After a period of 2-28 days, luciferase activity was determined via in vivo imaging system after intraperitoneal (i.p.) injection of luciferin substrate using a kodak In-Vivo Multispectral FX imager. The intravenous injected adenovirus usually harbored in the liver (>90%). In the non-tumor bearing mice that were injected with the original unmodified Ad-INSM1p-Luc2, it was observed that non-specific luciferase expression occurred and was focused primarily in the liver area. In contrast, both the first and second generation modified Ad-INSM1p-Luc2 did not exhibit non-specific luciferase expression after luciferin administration. To further demonstrate that the modified Ad-INSM1p-Luc2 virus maintains NE tumor specificity, an Ad-INSM1p-Luc2 pre-infected H1155 NE tumor was established in nude mice and showed readily tumor imaging by luciferase (Fig. 1I) . These results determined that the modified INSM1-promoter (both first and second generation) is essential in blocking the effects of adenoviral regulatory elements to retain tumor specificity in vivo.
Ad-INSM1p-Met displays INSM1 specificity in vitro.
We constructed an adenoviral vector to express secreted Metridia luciferase specifically driven by the modified INSM1-promoter for the detection of NE tumors. Secreted Metridia was measured in vitro by co-infecting tumor cells with Ad-INSM1p-Met vector (Ad-HS4ins-INSM1p-2xNRSE-Metridia) and Ad-SV40-Luc2. The addition of Ad-SV40-Luc2 virus was used to normalize the infection efficiency using the ratio between extracellular and intracellular luciferase activity. Both INSM1-negative and INSM1-positive tumor cell lines including lung carcinoma, neuroblastoma, medulloblastoma, pheochromocytoma, and insulinoma were infected with Ad-INSM1p-Met/Ad-SV40-Luc2 for 48 h (Fig. 2) . The secreted luciferase activity in the media was readily detected in all of (Fig. 2) . In contrast, the INSM1-negative tumor cell lines showed no secreted Metridia luciferase relative to intracellular luciferase. In order to assess the efficacy of INSM1-promoter driven Metridia luciferase adenoviral vector in xenograft human tumors, human tumor cultured cells derived from previously established xenograft tumor were collected and grown in culture. These ex vivo tumor cells were co-infected with Ad-INSM1p-Met and Ad-SV40-Luc2 to determine the ratio between extracellular and intracellular luciferase activity. After incubation for 3 days, it was determined that INSM1-positive cells [UMC-11, SK-N-Be(2), H1155, H69, except D283] infected by Ad-INSM1p-Met expressed extracellular Metridia luciferase that produced signals as high as 1.6 times the intracellular firefly luciferase (Fig. 3) . In contrast, INSM1-negative cells (HeLa and U87) produced low levels of extracellular Metridia luciferase that did not exceed 0.11 times the activity of intracellular firefly luciferase.
INSM1 promoter-driven Gaussia luciferase retains specificity. In preparation for further in vivo assays, we switched from Metridia luciferase to a Gaussia luciferase expression vector due to the increased stability of Gaussia luciferase in vivo. As recent studies have shown, Gaussia luciferase signals were detectable after tail-vein injection in mice, due to its increased temperature stability compared to Metridia luciferase (19) . To determine the specificity of our newly constructed Gaussia luciferase construct (Ad-INSM1p-Gau), we conducted an in vitro luciferase assay to evaluate whether our Ad-INSM1p-Gau vector (Ad-2xHS4Core-INSM1p-2xNRSE-Gaussia) could specifically express Gaussia luciferase in INSM1-positive cell lines in a similar manner as our Ad-INSMp-Met vector. After co-infection with Ad-INSM1p-Gau/Ad-SV40-Luc2, we were able to see significant secreted luminescent activity in the media of all INSM1-positive cell lines as compared to INSM1-negative control cell lines (Fig. 4) Ad-INSM1p-Gau and Ad-INSM1p-∆24E1A virus combination at a total concentration of 1x10 9 ifu (Fig. 6 ). After infection with the virus combination for 6 days, detectable luciferase signal was observed in the serum (p<0.01). The signal increased in intensity by day 9 and lasted up to 12 days, the humane endpoint for the tumor bearing animals. The Ad-INSM1p-Luc2 infected tumor released no Gaussia luciferase into the circulation and was used as the control.
Discussion
Although the original INSM1-promoter possesses NE-tumor specificity, it was discovered that the promoter loses its specificity when used in an adenoviral setting. In a recent study, Akerstrom et al demonstrated that an INSM1-promoter driven adenoviral reporter construct displayed non-specific expression after tail vein injection in an in vivo mouse model (22) . It was hypothesized that this loss of specificity was due to the presence of overpowering viral enhancers that were otherwise not present in normal cells. To override these adenoviral regulatory elements, an insulator sequence derived from the HS4 chicken β-globin insulator was placed upstream of the INSM1-promoter to block effects from any viral enhancers. In addition, two copies of the neuron-restrictive silencer element (NRSE), a regulatory element with dual functions to silence the INSM1 promoter in non-neuronal cells while enhancing it in neuronal cells, were placed downstream of the promoter. Once these elements were added, the modified INSM1-promoter was able to retain its high specificity in an adenoviral vector (22) . To further improve upon this original design, the present study replaced the 1.2-kb full insulator sequence with two copies of the HS4 core insulator (250 bp x 2) to create the second generation modified INSM1 promoter. Although the 1.2-kb full insulator sequence has been well characterized functionally, the 250-bp core insulator was observed to exhibit the same protective activity as the full sequence (23) . The main benefit of switching from a full insulator sequence to the core sequence is that utilization of two copies of the 250-bp core would free ~700 bp of space for the assembly of larger transgenic sequences in the viral vector. Essentially, this more compact form of the modified INSM1-promoter displays the same NE tumor specificity with the additional advantage of allowing more flexible cloning strategies.
Retaining the specificity of the INSM1-promoter in an adenoviral vector has allowed us to construct a Gaussia luciferase reporter vector that can detect the presence of NE tumor in vivo. When paired with a conditionally replicating oncolytic virus, the virus combination allowed for continuous expression of Gaussia luciferase for the duration of the tumor's progression. These results could have a significant impact on monitoring tumor progression during the treatment of patients. Given that the viruses can selectively replicate in NE tumor cells, Gaussia luciferase expression should persist and intensify as the tumor increases in size. Conversely, if treatment of the tumor is successful, luciferase expression in the patient's blood should decrease as tumor size is reduced. Our study is a proof in principle that the Gaussia vector can be used in combination with a treatment protocol to monitor a patient's treatment outcome. An alternative use for this virus during the treatment of a NE tumor would be to discern whether a tumor is removed completely after surgical resection. By injecting the virus combination into the resection site during the surgical procedure, clinicians would be able to monitor the presence of INSM1-positive NE tumor cells based on a Gaussia luciferase readings from the patient's blood. Continuous monitoring of expression levels would allow for a better prognosis in these patients post-procedure by alerting clinicians to an incomplete resection.
Using the Ad-INSM1p-Gau vector in combination with the Ad-INSM1p-∆24E1A was discovered to be more advantageous as compared to using Ad-INSM1p-Gau alone. In NE tumor cells infected by the virus combination, Gaussia luciferase expression was significantly higher than that of the Ad-INSM1p-Gau virus (20 MOI) alone after 6 days post-infection, even though the number of infectious units of Ad-INSM1p-Gau (10 MOI) was lower at the start for the combination. This indicates that the addition of ∆24E1A expression in cells infected by our Gaussia virus allowed for conditional replication of the reporter vector. This replication has the potential to significantly increase the copy number of the virus over several days, leading to an increase in sensitivity of Gaussia luciferase detection. Therefore, the most efficient method of increasing the sensitivity of infection seems to involve utilization of conditionally replicating viruses, as opposed to simply increasing the infectious units during administration of the virus.
Taken together, the Ad-INSM1p-Gau virus has the potential to be an easy-to-use and highly sensitive tool for the detection of NE tumors in the clinical setting. While a viral construct cannot be used as a diagnostic tool for the general population, it can be an alternative approach to track the tumor progression in patients with existing NE cancers. Additionally, it could also be used diagnostically in populations where a NE tumor is suspected. In these cases, the virus combination could act as both a diagnostic tool and as a way to monitor tumor progression.
